drugset / Trial / NCT05341115

A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

NCT05341115

Phase 4 Completed 80 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The main aim is to see how leuprolide works to treat central precocious puberty in children. Participants will receive an injection of leuprorelin acetate depot 11.25 mg every 12 weeks during 6 months and will visit their study clinic 6 times to complete some assessments.

Timeline

Start
2023-03-14
Primary completion
2024-12-19
Completion
2025-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Leuprolide Other / unclassified 11.25 mg Subcutaneous